- 1 Title: Estimated incidence rate of specific cardiovascular
- 2 and respiratory hospitalizations attributable to
- **Respiratory Syncytial Virus among adults in Germany**
- 4 between 2015 and 2019
- 5

6 Author Details:

- 7 Caihua Liang¹, Aleksandra Polkowska-Kramek², Caroline Lade³, Lea Johanna
- 8 Bayer³, Robin Bruyndonckx², Bennet Huebbe³, Worku Biyadgie Ewnetu², Pimnara
- 9 Peerawaranun², Maribel Casas², Thao Mai Phuong Tran², Gordon Brestrich³,
- 10 Christof von Eiff³, Bradford D. Gessner¹, Elizabeth Begier⁴, Gernot Rohde⁵

11

12 **Affiliations:**

- 13 ¹ Pfizer Inc-New York (USA)
- 14 ² P95 Epidemiology & Pharmacovigilance, Leuven, Belgium
- 15 ³ Pfizer Pharma GmbH Berlin (Germany)
- 16 ⁴ Pfizer Inc Dublin (Ireland)
- ⁵ Goethe University Frankfurt, University Hospital, Medical Clinic I, Department of
- 18 Respiratory Medicine, Frankfurt/Main, Germany

19

20 Corresponding author:

- 21 Caihua Liang
- 22 Email: <u>caihua.liang@pfizer.com</u>
- 23 Address: 66 Hudson Blvd E, New York, NY 10001

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 Abstract

Introduction: Respiratory syncytial virus (RSV) can cause severe outcomes among
adults. However, RSV incidence in adults is frequently underestimated due to nonspecific symptomatology, limited standard-of-care testing, and lower test sensitivity
compared to infants. We conducted a retrospective observational study to estimate
RSV-attributable incidence of hospitalizations among adults in Germany between 2015
and 2019.

31 **Methods:** Information on hospitalizations and the number of people at risk of 32 hospitalization (denominator) was gathered from a Statutory Health Insurance (SHI) 33 database. A quasi-Poisson regression model accounting for periodic and aperiodic time 34 trends and virus activity was fitted to estimate the RSV-attributable incidence rate 35 (IR) of four specific cardiovascular hospitalizations (arrhythmia, ischemic heart 36 diseases, chronic heart failure exacerbations, cerebrovascular diseases) and four 37 specific respiratory hospitalizations (influenza/pneumonia, bronchitis/bronchiolitis, 38 chronic lower respiratory tract diseases, upper respiratory tract diseases).

39 **Results**: RSV-attributable IRs of hospitalizations were generally increasing with age.

40 Among cardiovascular hospitalizations in adults aged \geq 60 years, arrhythmia and

41 ischemic heart diseases accounted for the highest incidence of RSV-attributable

42 events, followed by chronic heart failure exacerbation, with annual IR ranges of 157–

43 260, 133–214, and 105–169 per 100,000 person-years, respectively. The most

44 frequent RSV-attributable respiratory hospitalizations in adults aged \geq 60 years were

45 for chronic lower respiratory tract diseases and bronchitis/bronchiolitis, with annual IR

46 ranges of 103–168 and 77–122 per 100,000 person-years, respectively.

47 **Conclusion**: RSV causes a considerable burden of respiratory and cardiovascular
48 hospitalizations in adults in Germany, similar to other respiratory viruses (e.g.,

- 49 influenza and SARS-CoV-2). This highlights the need to implement effective
- 50 prevention strategies, especially for older adults.

51 Keywords:

52 RSV, cardiorespiratory, hospitalization, Germany, quasi-Poisson, time-series modeling

53 Key Summary Points:

- Respiratory syncytial virus (RSV) disease burden in adults is significant yet
- 55 often remains unrecognized due to unspecific symptoms, lack of routine testing
- and lower test sensitivity compared to infants.
- Using a quasi-Poisson regression time-series model, we estimated the age stratified RSV-attributable incidence of specific cardiovascular and respiratory
 hospitalizations in Germany between 2015 and 2019.
- Estimated cardiorespiratory RSV hospitalization rates increased with age and
- 61 were significantly higher in older adults.
- Arrhythmia, ischemic heart diseases, and chronic lower respiratory tract
 disease exacerbation were the most frequent causes of RSV-attributable
 cardiovascular and respiratory hospitalizations.
- RSV causes a considerable burden of respiratory and cardiovascular
- 66 hospitalizations among adults in Germany, and effective RSV vaccines could
- 67 improve public health outcomes, especially for older adults.

68 Introduction

Respiratory syncytial virus (RSV) usually causes mild respiratory infections but
may also lead to severe lower respiratory tract diseases such as chronic
obstructive pulmonary disease exacerbation and pneumonia (1). RSV affects
people of any age, but the risk of severe infections and hospitalizations is highest
among infants, adults aged 60 years and above, and those with comorbidities (14).

75 The incidence rate (IR) and clinical burden of RSV disease in adults are 76 challenging to measure due to symptoms resembling influenza and other co-77 circulating respiratory viruses (5). Limited standard-of-care RSV testing among 78 adults, single specimen collection (i.e., use of nasopharyngeal/nasal swab only) 79 and reduced sensitivity of diagnostic testing compared to children (6-9) contribute to the underestimation of the RSV burden. Additionally, inadequate RSV diagnostic 80 81 capacity in many healthcare facilities (5, 8, 10, 11) and low awareness of RSV, 82 particularly for patients with cardiopulmonary manifestations, hinder measuring 83 the actual RSV burden (12). Further, even when RSV is diagnosed via laboratory 84 testing, other non-specific acute respiratory infection codes may be used for 85 administrative diagnoses (13).

RSV-associated exacerbation of underlying cardiopulmonary diseases may
contribute to a large and unrecognized burden of RSV disease (12). Several
studies demonstrated that RSV can cause exacerbation of asthma and chronic
obstructive pulmonary disease (COPD) (14-17) (18). Growing evidence indicates
that RSV is associated with cardiovascular diseases such as acute myocardial
infarction, stroke, arrhythmia, exacerbation of congestive heart failure (CHF), and

92 coronary artery disease (CAD) (12, 19-26). Nonetheless, data on RSV-attributable
93 cardiovascular hospitalizations in adults is limited.

94 Due to severe under-ascertainment of RSV cases in adults, the recent burden of

95 RSV estimates is more commonly based on mathematical models. Those models

96 relate the temporal variability of the community activity of RSV (indicated by, e.g.,

97 week-to-week RSV disease case counts) to the variability in disease outcomes that

98 may be caused or triggered by an RSV infection (e.g., COPD exacerbation

99 hospitalizations and cardiovascular hospitalizations). Among those outcomes, the

100 model estimates the portion expected to be RSV-attributable (10, 27-29).

101 In Germany, data on the RSV burden from prospective observational incidence

102 studies are unavailable (30), but a recent model-based study showed considerable

103 RSV morbidity and mortality between 2015 and 2019 (31). The estimated RSV-

104 attributable hospitalization IRs increased with age, with high rates observed

among people 60 years and above (respiratory diseases: 236–363 per 100,000

106 person-years; cardiovascular diseases: 558–885 per 100,000 person-years; and

107 cardiorespiratory diseases: 584–912 per 100,000 person-years) (31). However,

108 detailed data on RSV-attributable hospitalizations in more specific respiratory and

109 cardiovascular subgroups are still lacking.

Providing such estimates would help to better understand the burden imposed by RSV and guide the formulation of vaccine policies. Lately, RSV vaccines have been licensed to prevent lower respiratory tract disease caused by RSV in adults 60 years and above. Two RSV vaccines [GSK's RSV Arexvy vaccine (32) and Pfizer's RSV Abrysvo vaccine (33)] for adults aged 60 years and above have been available in Germany since 2023. In 2024, market authorization received a third

116 RSV vaccine [Moderna's mRESVIA vaccine] (34).

- 117 We conducted a model-based study to estimate RSV-attributable hospitalizations
- 118 of four respiratory (influenza/pneumonia, bronchitis/bronchiolitis, chronic lower
- 119 respiratory tract diseases, upper respiratory tract diseases) and four
- 120 cardiovascular (chronic heart failure exacerbation, ischemic heart diseases,
- arrhythmia, cerebrovascular diseases) conditions in Germany.

122 Methods

123 Study design

124 We conducted an observational retrospective study to estimate the IRs of specific

- 125 respiratory and cardiovascular hospitalizations attributable to RSV among adults in
- 126 Germany using a quasi-Poisson regression model.

127 Data sources

128 Data on hospitalizations was sourced from the Deutsche Analysedatenbank für

129 Evaluation und Versorgungsforschung (DADB) database from Gesundheitsforen

130 Leipzig (GFL). This database contains Statutory Health Insurance (SHI) data of

approximately 3.5 million insured individuals. Participants included in the study

132 were adults aged 18 years and above. The age and sex structure of the DADB

133 database is similar to that of the German population, with adjustment factors to

account for a slightly younger population in DADB available (35). The study

period, from 2015 to 2019, was selected to avoid any distortions in RSV

epidemiology due to the COVID-19 pandemic (36).

137 The study included eight disease outcomes, coded according to the German

138 Modification (GM) of the International Classification of Diseases, 10th revision

- 139 (ICD-10-GM). These include four specific respiratory outcomes [influenza/
- 140 pneumonia (J10-J18), bronchitis/bronchiolitis (J20-J22), chronic lower respiratory
- 141 tract diseases (J40-J47), upper respiratory tract diseases (J00-J06, J30-J39)], and

142 four specific cardiovascular outcomes [chronic heart failure (I42-I43, I50, I51.7),

143 ischemic heart diseases (I20-I25), arrhythmias (I44-I49), and cerebrovascular

144 diseases (I60-I68)]. To compare the difference between the number of observed

145 (reported in the database) and attributable (model-based) RSV events, we

obtained RSV-specific hospitalizations (B97.4, J21.0, J12.1, J20.5) stratified by

147 age group.

148 Hospitalization was defined as an overnight stay in a hospital commencing from

149 the admission date. If subsequent hospitalizations for the same outcome occurred

150 within 30 days from discharge, these were collapsed with the initial hospitalization

151 to avoid overcounting cases due to readmission.

152 Individuals were categorized into four age groups: 18-44, 45-59, 60-74, and 75

153 years and above. The 60-year and above cut-off was selected because RSV

154 vaccines are approved for this age group in Germany. For anonymization

155 purposes, data were suppressed if fewer than 5 cases were reported in the age

156 group and outcome stratum.

157 The indicator for RSV circulation was defined as the weekly number of RSV-related

158 hospitalizations in children under two years of age (ICD-10-GM codes: B97.4,

159 J21.0, J12.1, J20.5, J21.9). As in other studies (10, 26, 28, 37), we selected RSV

160 circulation in children due to the higher frequency of testing and hospitalization in

this age group and the higher sensitivity of diagnostic tests compared to adults (8,

162 38). As most bronchiolitis cases in young children are caused by RSV, we also

163 included J21.9 (acute bronchiolitis, unspecified) (39-41) as a proxy for RSV

164 circulation. The indicator for influenza circulation was defined as the weekly

number of influenza-specific hospitalizations (ICD-10-GM codes: J09, J10, J11) in

adults aged 60 years and above (37).

167 Statistical analysis

- Upon observation of seasonality, age-group-stratified weekly aggregated data were modeled using a quasi-Poisson regression model. The model was constructed according to the previously published protocol (42). The model accounts for baseline periodic and aperiodic time trends, viral activity (RSV and influenza) and potential overdispersion.
- 173 With these fitted models, we obtained the annual number of RSV-attributable
- events and the proportion of RSV-attributable events for each outcome and age
- 175 group as described in the protocol (42).
- 176 Yearly IRs of RSV-attributable events, expressed in the number of events per
- 177 100,000 person-years, were obtained by dividing the annual model-based number
- 178 of RSV-attributable events by the population at risk. This age-specific population
- 179 at risk of the event was obtained from the DADB database. No effort was made to
- 180 limit the denominator to persons at risk for the given condition (e.g., estimate
- 181 COPD exacerbation incidence only among persons with COPD diagnosis). Because
- 182 the DADB database, from which our estimates were obtained, has a slightly
- 183 younger population compared to the overall German population covered by SHI,
- 184 the yearly RSV-attributable events were multiplied with age-specific correction
- 185 factors based on data provided by GFL to scale the IRs to a nationally
- 186 representative level.
- 187 Confidence intervals were obtained via residual bootstrapping. All data
- 188 management and statistical analyses were conducted using R software (version189 4.0.4).
- 190
- 191

192 Ethical considerations

This study used aggregated and anonymized data, therefore not requiring approval from Institutional Review Boards or Ethical Committees or informed consent from patients. The study was conducted following legal and regulatory requirements and research practices described in the Good Epidemiological Practice guidelines issued by the International Epidemiological Association (43).

198

199 **Results**

200 Observed hospitalizations

201 Between 2015 and 2019, the diagnoses with the largest number of

202 hospitalizations were due to arrhythmia and ischemic heart diseases, responsible

for 266,463 and 259,052 hospitalizations, respectively. Among respiratory

204 hospitalizations, chronic lower respiratory tract diseases were responsible for

205 162,344 hospitalizations, with influenza/pneumonia (74,064 hospitalizations)

accounting for the most (Supplementary Table 1). The majority of hospitalizations,

amounting to 70% or more, involved individuals aged 60 years and above. The

208 exception to this trend was observed in upper respiratory tract diseases, where

209 most hospitalizations (74% or more) occurred in younger adults aged 18-59

210 years.

211 The reported number of RSV-specific hospitalizations based on ICD code

212 diagnoses alone throughout the study period was 24 cases across all age groups.

213 However, the total number of RSV-specific hospitalizations is unknown as, during

214 most weeks in which RSV-specific hospitalizations were reported, counts were

215 below five and hence suppressed for anonymity.

217 Estimated RSV-attributable hospitalizations

- 218 The estimated IR of RSV-attributable diseases showed year-to-year fluctuations,
- with the highest incidence observed for most outcomes in 2017. Due to a lack of
- adequate seasonal fluctuations, several outcomes were not modeled in the
- youngest age group. For cerebrovascular diseases, only data for the age group 75
- 222 years and above were suitable for modeling (Table 1 and Table 2).
- 223 The estimated IR of RSV-attributable respiratory hospitalizations in the age group
- 60 years and above was highest for chronic lower respiratory tract diseases (range
- across the study period: 103-168 hospitalizations per 100,000) and bronchitis/
- bronchiolitis (77-122 hospitalizations per 100,000) (Table 1). The IRs of RSV-
- attributable bronchitis/bronchiolitis hospitalizations for those aged 75 years and
- above were approximately 11- to 12-fold and 32- to 43-fold higher than the rates
- for adults aged 60-74 years and 45-59 years, respectively. Similarly, the rates of
- chronic lower respiratory diseases were approximately 3- to 4-fold and 12- to 15-
- fold higher in the oldest age group (\geq 75 years) compared to younger age groups
- 232 (60-74 and 45-59 years) (Table 1).
- 233 RSV-attributable proportions were comparable between age groups and
- respiratory subgroups (range 1-5% in age groups 45-59 years and 60-74 years,
- and 3-8% in \geq 75 years) with the exception of bronchitis or bronchiolitis where the
- 236 RSV-attributable proportion was 1-10% for younger age groups and 17-25% for
- adults 75 years and above (Table 1). For cardiovascular causes, arrhythmia (157-
- 238 260 per 100,000 person-years) and ischemic heart diseases (133-215 per
- 239 100,000 person-years), followed by chronic heart failure (105-169 per 100,000
- 240 person-years) showed the highest RSV-attributable IRs (Table 2) in adults aged
- \geq 60 years. The RSV-attributable IRs were notably higher in older age groups,
- 242 particularly among hospitalized individuals aged 75 years and above. The rates of

RSV-attributable arrhythmia and ischemic heart disease hospitalizations for those
aged 75 and above were both approximately 4-fold higher than the rates for
adults aged 60-74 years. Moreover, these rates were about 25-fold and 21-fold
higher, respectively, than for adults aged 45-59 years (Table 2). RSV-attributable
proportions were comparable between age groups and cardiovascular subgroups,
accounting for approximately 1% to 3% of all hospitalizations (Table 2).

249

250 Discussion

251 Our study complements the results of the first model-based study in Germany 252 (31) by providing estimates on specific types of cardiorespiratory hospitalizations 253 attributable to RSV. We found a high burden of cardiovascular hospitalizations 254 related to RSV, with RSV-attributable IRs for arrhythmia (157-260 per 100,000 255 person-years) and ischemic heart diseases (133-215 per 100,000 person-years) 256 being the two highest among all studied conditions in adults aged 60 years and 257 above. Among respiratory conditions, chronic lower respiratory tract diseases 258 (103-168 per 100,000 person-years) and bronchitis/bronchiolitis (77-122 per 259 100,000 person-years) had the highest RSV-attributable incidences in adults aged 260 60 years and over. As in other studies, we found that RSV-attributable IRs were 261 increasing with age, with a considerable surge observed in patients aged 60 years 262 and older. Our findings were considerably higher than those based on RSV-specific 263 ICD-10 codes alone, suggesting vast under-ascertainment of RSV cases in adults. 264 Substantially lower RSV hospitalization rates in adults aged >59 years (0.11-265 11.36 per 100,000 person-years) were also reported in an observational study in 266 Germany, which was based on data on primary discharge diagnosis of RSV (J21.1, 267 J20.5, J21.0) (44).

268 Our study adds to the growing evidence of the association between RSV circulation 269 and cardiovascular events. We found that approximately 2% to 3% of 270 hospitalizations due to arrhythmia, ischemic heart diseases, and chronic heart 271 failure in people 60 years and above were attributed to RSV. In the oldest age 272 group (75 years and above), we also found an association – in line with another 273 study – between RSV and cerebrovascular diseases, with 1% to 2% of those 274 hospitalizations being attributable to RSV. For instance, in Spain, the RSV-275 attributable proportion of ischemic heart diseases in adults aged 60 years and 276 above (3%) and cerebrovascular diseases in adults aged 80 years and above (2%) 277 were comparable to our results (26). Although the RSV-attributable proportions 278 were comparable, it resulted in higher IRs, most likely due to overall higher 279 observed hospitalizations due to cardiovascular causes in Germany. This might be 280 related to different coding practices or different prevalence of comorbidities in 281 those two populations.

282 Several mechanisms are considered to explain the relationship between RSV and 283 cardiovascular events. Part of those conditions may be related to the indirect 284 effect of inflammation due to acute respiratory infections. Inflammation may 285 increase the concentration of C-reactive protein, inflammatory cytokines and 286 clotting factors such as fibringen, leading to an increased risk of thrombotic 287 coronary occlusion (20, 45, 46). Additionally, it may cause endothelial dysfunction 288 and inhibit the function of vasodilating nitric oxide or prostaglandins, contributing 289 to arterial and venous thromboembolic disease (47). Development of pulmonary 290 hypertension may lead to secondary myocardial dysfunction, hypotension and 291 arrhythmia (24). RSV can also directly infect organs, as it was isolated from 292 myocardial tissue biopsies in patients with myocarditis (19, 24). Cardiovascular 293 diseases remain the leading cause of morbidity and mortality worldwide (48).

Thus, the potential impact of a vaccine preventing cardiovascular events, as observed for the influenza vaccine (49, 50), might be substantial.

296 Our estimates for RSV-attributable hospitalizations due to bronchitis/ bronchiolitis 297 (77-122 per 100,000) and influenza/pneumonia diagnosis grouping (67-98 per 298 100,000) in adults aged 60 years and above align with the study conducted in 299 Spain (100-110 per 100,000 and 83-91 and, respectively) (26). The Spanish 300 study utilized the same generic protocol that we used for this study. In contrast, 301 when compared to another model-based study from the United Kingdom, IRs in 302 older age groups (65-74 and \geq 75 years) were considerably higher in Germany 303 (10). The possible reason is using different methods (quasi-Poisson regression 304 modeling weekly counts vs linear regression modeling weekly outcome rates) and 305 a different RSV proxy definition (weekly hospitalizations due to RSV vs weekly RSV 306 counts from the surveillance system). We used RSV hospitalization data as a 307 proxy because hospitalization data is less affected by the testing practices than 308 the surveillance data, which will be mostly driven by influenza (data not shown). 309 Further, the UK study used primary diagnosis codes, which have been shown to 310 underestimate incidence in validation studies (51).

311 Among age groups 45-59 and 60-74 years, the highest RSV-attributable IR was 312 revealed for chronic lower respiratory tract diseases. Respiratory viruses, including 313 RSV, are known causes of exacerbation of COPD (16). In prospective cohort 314 studies, approximately 4% to 11% of COPD patients tested positive for RSV (52, 315 53). The prevalence of COPD is increasing globally, leading to enormous 316 healthcare costs and high mortality (54, 55). Exacerbation of COPD is associated 317 with an accelerated decline in lung function, progression of the disease and lower 318 quality of life (15). Thus, preventing COPD exacerbation should be a public health 319 priority, and vaccination of COPD patients should be prioritized, as suggested by

the recent recommendation from the US Centers for Disease Control andPrevention (56).

Our study showed considerable under-ascertainment of RSV cases in adults in
Germany. Other studies also observed low testing activity and considerable
underestimation of the RSV burden in adults (8, 9, 26) when only RSV-specific
ICD codes are used. These findings highlight the need for systematic testing and
reporting, including patients presenting with cardiovascular manifestations or
exacerbation of underlying respiratory diseases.

328 The main strength of our study was the use of a large database of approximately 329 3.5 million insured persons, an extended study period of five years and the 330 inclusion of eight different medical conditions, allowing for a more sensitive 331 estimation of the RSV burden. In addition, our study was based on a generic 332 protocol (42) that permits robust comparisons between countries. The protocol 333 was developed based on an extensive prior literature review and experts' input. 334 We also acknowledge some study limitations. Our model included only RSV and 335 influenza as viral indicators, assuming those are the only pathogens related to the 336 outcome of interest. However, by inclusion of the periodic component and 337 overdispersion parameter, we indirectly accounted for other potentially relevant 338 pathogens. Second, RSV hospitalizations in children less than two years old as the 339 RSV indicator may not fully reflect viral activity in adults. However, the pattern in 340 adults is similar to that observed in children, and for the model performance, the 341 most important factor is the fluctuation over time rather than the absolute 342 numbers. Third, although the SHI database is representative of the German 343 population, the age distribution is slightly skewed towards young individuals. To 344 account for this difference, we used correction factors to standardize for age in the

incidence calculation. Lastly, we did not limit the population denominators to those

- individuals at risk of a specific condition (e.g., limit the denominator for the RSV-
- 347 attributable COPD events to those with COPD diagnosis), which would likely
- 348 increase the reported incidence rate.
- 349 In conclusion, our study showed a high and largely unrecognized cardiovascular
- and respiratory burden of RSV among adults in Germany. Substantial
- 351 underestimation of RSV cases emphasizes the need for standard-of-care testing,
- also among adults with cardiovascular symptoms. Newly introduced vaccines
- 353 might have a high impact, not only on respiratory hospitalization but also on
- 354 cardiac hospitalizations.
- 355

356 Acknowledgements

- 357 Funding
- 358 This study was funded by Pfizer Ltd.

359 Medical Writing, Editorial, and Other Assistance

- 360 Editorial assistance in the preparation of this article was provided by Dr. Somsuvro
- 361 Basu of P95. Support for this assistance was funded by Pfizer Ltd.

362 Data availability

- 363 The datasets generated and/or analyzed during this study are not publicly
- 364 available (data provider's restrictions). Weekly counts of hospitalized cases and
- 365 extrapolation factors were provided by the Gesundheitsforen Leipzig GmbH.
- 366

368 Conflicts of interests

- 369 Aleksandra Polkowska-Kramek, Robin Bruyndonckx, Worku Biyadgie Ewnetu,
- 370 Pimnara Peerawaranun, Maribel Casas, Thao Mai Phuong Tran are employees of
- 371 P95 Epidemiology & Pharmacovigilance, which received funding from Pfizer to
- 372 conduct the research described in this manuscript and for manuscript
- 373 development. Caihua Liang, Caroline Lade, Lea Johanna Bayer, Bennet Huebbe,
- 374 Gordon Brestrich, Christof von Eiff, Bradford D. Gessner, and Elizabeth Begier are
- 375 Pfizer employees and may own Pfizer stock. Gernot Rohde is an expert in the field
- of RSV and received an honorarium from Pfizer for input on the study design.

378 **References**

1. Falsey AR. Respiratory syncytial virus infection in adults. *Semin Respir Crit Care Med* 2007;28:171-81.

381 2. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory
382 syncytial virus infection in elderly and high-risk adults. *N Engl J Med*383 2005;352:1749-59.

384 3. Falsey AR. Respiratory Syncytial Virus Infection in Elderly Adults. *Drugs* 385 *Aging* 2005;22:578-87.

386 4. Njue A, Nuabor W, Lyall M, Margulis A, Mauskopf J, Curcio D, et al.
387 Systematic Literature Review of Risk Factors for Poor Outcomes Among Adults
388 With RSV Infection in High-Income Countries. *Open Forum Infect Dis*389 2023;ofad513.

390 5. Rozenbaum MH, Begier E, Kurosky SK, Whelan J, Bem D, Pouwels KB, et al.
391 Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of
392 Current Data. *Infect Dis Ther* 2023;12:1487-504.

Ramirez J, Carrico R, Wilde A, Junkins A, Furmanek S, Chandler T, et al.
Diagnosis of Respiratory Syncytial Virus in Adults Substantially Increases When
Adding Sputum, Saliva, and Serology Testing to Nasopharyngeal Swab RT-PCR. *Infect Dis Ther* 2023;12:1593-603.

397 7. Onwuchekwa C, Moreo LM, Menon S, Machado B, Curcio D, Kalina W, et al.
398 Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to
399 Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis.
400 *J Infect Dis* 2023;228:173-84.

8. Rozenbaum MH, Judy J, Tran D, Yacisin K, Kurosky SK, Begier E. Low Levels
of RSV Testing Among Adults Hospitalized for Lower Respiratory Tract Infection in
the United States. *Infect Dis Ther* 2023;12:677-85.

404 9. McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of
405 Medically Attended RSV Among US Adults: A Systematic Review and Meta406 analysis. *Open Forum Infect Dis* 2022;9:ofac300.

Fleming DM, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, et
al. Modelling estimates of the burden of Respiratory Syncytial virus infection in
adults and the elderly in the United Kingdom. *BMC Infect Dis* 2015;15:443.

410 11. Ambrosch A, Luber D, Klawonn F, Kabesch M. Focusing on severe infections
411 with the respiratory syncytial virus (RSV) in adults: Risk factors, symptomatology
412 and clinical course compared to influenza A / B and the original SARS-CoV-2
413 strain. J Clin Virol 2023;161:105399.

414 12. Branche AR, Saiman L, Walsh EE, Falsey AR, Sieling WD, Greendyke W, et
415 al. Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults,
416 2017-2020. *Clin Infect Dis* 2022;74:1004-11.

417 13. Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, et al. Evaluation
418 of using ICD-10 code data for respiratory syncytial virus surveillance. *Influenza*419 *Other Respir Viruses* 2020;14:630-7.

420 14. Adeli M, El-Shareif T, Hendaus MA. Asthma exacerbation related to viral 421 infections: An up to date summary. *J Family Med Prim Care* 2019;8:2753-9.

Linden D, Guo-Parke H, Coyle PV, Fairley D, McAuley DF, Taggart CC, et al.
Respiratory viral infection: a potential "missing link" in the pathogenesis of COPD. *Eur Respir Rev* 2019;28.

Rohde G, Wiethege A, Borg I, Kauth M, Bauer TT, Gillissen A, et al.
Respiratory viruses in exacerbations of chronic obstructive pulmonary disease

427 requiring hospitalisation: a case-control study. *Thorax* 2003;58:37-42.

Ramaswamy M, Groskreutz DJ, Look DC. Recognizing the importance of
respiratory syncytial virus in chronic obstructive pulmonary disease. *Copd*2009;6:64-75.

431 18. Westerly BD, Peebles RS, Jr. Respiratory syncytial virus infections in the
432 adult asthmatic--mechanisms of host susceptibility and viral subversion. *Immunol*433 *Allergy Clin North Am* 2010;30:523-39, vi-vii.

- Ivey KS, Edwards KM, Talbot HK. Respiratory Syncytial Virus
 and Associations With Cardiovascular Disease in Adults. *J Am Coll Cardiol*2018;71:1574-83.
- Bosco E, van Aalst R, McConeghy KW, Silva J, Moyo P, Eliot MN, et al.
 Estimated Cardiorespiratory Hospitalizations Attributable to Influenza and
 Respiratory Syncytial Virus Among Long-term Care Facility Residents. *JAMA network open* 2021;4:e2111806.
- 441 21. Kawashima H, Inagaki N, Nakayama T, Morichi S, Nishimata S, Yamanaka
 442 G, et al. Cardiac Complications Caused by Respiratory Syncytial Virus Infection:
 443 Questionnaire Survey and a Literature Review. *Glob Pediatr Health*
- 444 2021;8:2333794x211044114.
- 445 22. Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal
 446 Influenza Infections and Cardiovascular Disease Mortality. *JAMA Cardiol*447 2016;1:274-81.
- 448 23. Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial
 449 virus infection--a systematic review. *Crit Care* 2006;10:R107.
- 450 24. Gkentzi D, Dimitriou G, Karatza A. Non-pulmonary manifestations of 451 respiratory syncytial virus infection. *J Thorac Dis* 2018;10:S3815-s8.
- 452 25. Franczuk P, Tkaczyszyn M, Kulak M, Domenico E, Ponikowski P, Jankowska
 453 EA. Cardiovascular Complications of Viral Respiratory Infections and COVID-19.
 454 *Biomedicines* 2022;11.
- 455 26. Haeberer M, Bruyndonckx R, Polkowska-Kramek A, Torres A, Liang C,
 456 Nuttens C, et al. Estimated Respiratory Syncytial Virus-Related Hospitalizations
 457 and Deaths Among Children and Adults in Spain, 2016-2019. *Infect Dis Ther*458 2024.
- 459 27. Matias G, Taylor RJ, Haguinet F, Schuck-Paim C, Lustig RL, Shinde V.
 460 Estimates of mortality attributable to influenza and RSV in the United States
 461 during 1997-2009 by influenza type or subtype, age, cause of death, and risk
 462 status. *Influenza and other respiratory viruses* 2014;8:507-15.
- 463 28. Goldstein E, Greene SK, Olson DR, Hanage WP, Lipsitch M. Estimating the
 464 hospitalization burden associated with influenza and respiratory syncytial virus in
 465 New York City, 2003-2011. *Influenza Other Respir Viruses* 2015;9:225-33.
- 466 29. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et 467 al. Hospitalizations associated with influenza and respiratory syncytial virus in the 468 United States, 1993-2008. *Clinical infectious diseases : an official publication of* 469 *the Infectious Diseases Society of America* 2012;54:1427-36.
- 470 30. Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, et al.
 471 Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden
 472 of Older Adults in High-Income Countries: a Systematic Review and Modelling
 473 Study. *Infect Dis Ther* 2023;12:1137-49.
- 474 31. Polkowska-Kramek A, Begier E, Bruyndonckx R, Liang C, Beese C, Brestrich
 475 G, et al. Estimated Incidence of Hospitalizations and Deaths Attributable to
 476 Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015
- 477 and 2019. *Infect Dis Ther* 2024.

478 32. Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, et
479 al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. *N Engl J*480 *Med* 2023;388:595-608.

33. Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, et al.
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. *N Engl J Med* 2023;388:1465-77.

484 34. Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R).

485 https://investors.modernatx.com/news/news-details/2024/Moderna-Receives-

486 <u>U.S.-FDA-Approval-for-RSV-Vaccine-mRESVIAR/default.aspx</u>.

- 487 35. GmbH GL. Deutsche Analysedatenbank für Evaluation und
- 488 Versorgungsforschung, Stand Januar. 2022.

489 <u>https://www.gesundheitsforen.net/GFL/Services/Analytik/Gesundheitsforen%20Le</u>
 490 <u>ipzig DADB Q1%202024.pdf</u>. Date last accessed: 19.04.2024 2024.

491 36. Oh DY, Buda S, Biere B, Reiche J, Schlosser F, Duwe S, et al. Trends in 492 respiratory virus circulation following COVID-19-targeted nonpharmaceutical 493 interventions in Germany, January - September 2020: Analysis of national 494 surveillance data. *Lancet Reg Health Eur* 2021;6:100112.

37. Zheng Z, Warren JL, Shapiro ED, Pitzer VE, Weinberger DM. Estimated
incidence of respiratory hospitalizations attributable to RSV infections across age
and socioeconomic groups. *Pneumonia (Nathan)* 2022;14:6.

498 38. Casiano-Colón AE, Hulbert BB, Mayer TK, Walsh EE, Falsey AR. Lack of 499 sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus 500 infection in adults. *J Clin Virol* 2003;28:169-74.

Sol 39. Calvo C, Pozo F, García-García ML, Sanchez M, Lopez-Valero M, Pérez-Breña
P, et al. Detection of new respiratory viruses in hospitalized infants with
branchialities a threa year prospective study. Acta Paediatr 2010;00:882. 7

bronchiolitis: a three-year prospective study. *Acta Paediatr* 2010;99:883-7.
40. Mansbach JM, Piedra PA, Teach SJ, Sullivan AF, Forgey T, Clark S, et al.
Prospective multicenter study of viral etiology and hospital length of stay in

506 children with severe bronchiolitis. *Arch Pediatr Adolesc Med* 2012;166:700-6.

41. Kenmoe S, Kengne-Nde C, Ebogo-Belobo JT, Mbaga DS, Fatawou Modiyinji
A, Njouom R. Systematic review and meta-analysis of the prevalence of common
respiratory viruses in children < 2 years with bronchiolitis in the pre-COVID-19
pandemic era. *PLoS One* 2020;15:e0242302.

42. Bruyndonckx R, Polkowska-Kramek A, Liang C, Nuttens C, Tran TMP,
Gessner BD, et al. Estimation of Symptomatic Respiratory Syncytial Virus Infection
Incidence in Adults in Multiple Countries: A Time-Series Model-Based Analysis
Protocol. *Infect Dis Ther* 2024.

515 43. Good Epidemiological Practice. Guidelines for Proper Conduct of 516 Epidemiological Research, (2007).

517 44. Niekler P, Goettler D, Liese JG, Streng A. Hospitalizations due to respiratory
518 syncytial virus (RSV) infections in Germany: a nationwide clinical and direct cost
519 data analysis (2010-2019). *Infection* 2023.

520 45. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory-tract 521 infections and risk of first-time acute myocardial infarction. *Lancet* 522 1998;351:1467-71.

523 46. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of 524 myocardial infarction and stroke after acute infection or vaccination. *N Engl J Med* 525 2004;351:2611-8.

526 47. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does 527 acute endothelial dysfunction provide a link? *Lancet* 1997;349:1391-2.

48. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM,
et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019:
Update From the GBD 2019 Study. *J Am Coll Cardiol* 2020;76:2982-3021.
49. Zangiabadian M, Nejadghaderi SA, Mirsaeidi M, Hajikhani B, Goudarzi M,

Goudarzi H, et al. Protective effect of influenza vaccination on cardiovascular
diseases: a systematic review and meta-analysis. *Sci Rep* 2020;10:20656.

- 534 50. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza 535 vaccination and reduction in hospitalizations for cardiac disease and stroke among 536 the elderly. *N Engl J Med* 2003;348:1322-32.
- 537 51. Hanquet G, Theilacker C, Vietri J, Sepúlveda-Pachón I, Menon S, Gessner B,
 538 et al. Best Practices for Identifying Hospitalized Lower Respiratory Tract Infections
 539 Using Administrative Data: A Systematic Literature Review of Validation Studies.
 540 *Infect Dis Ther* 2024;13:921-40.
- 541 52. Wiseman DJ, Thwaites RS, Ritchie AI, Finney L, Macleod M, Kamal F, et al. 542 RSV-related Community COPD Exacerbations and Novel Diagnostics: A Binational 543 Prospective Cohort Study. *Am J Respir Crit Care Med* 2024.

544 53. Colosia AD, Yang J, Hillson E, Mauskopf J, Copley-Merriman C, Shinde V, et 545 al. The epidemiology of medically attended respiratory syncytial virus in older

- adults in the United States: A systematic review. *PLoS One* 2017;12:e0182321.
 54. Agarwal D. COPD generates substantial cost for health systems. *Lancet Glob*
- 548 *Health* 2023;11:e1138-e9.

549 55. Chen S, Kuhn M, Prettner K, Yu F, Yang T, Bärnighausen T, et al. The global 550 economic burden of chronic obstructive pulmonary disease for 204 countries and 551 territories in 2020-50: a health-augmented macroeconomic modelling study. 552 *Lancet Glob Health* 2023;11:e1183-e93.

553 56. Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, et al. Use of 554 Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the 555 Advisory Committee on Immunization Practices - United States, 2023. *MMWR* 556 *Morb Mortal Wkly Rep* 2023;72:793-801.

- 557
- 558
- 559
- 560
- 561
- 562
- 563
- 564
- 565
- 566
- 567

Tables

Table 1 Estimated incidence rate per 100,000 person-years of RSV-attributable respiratory hospitalizations and percentage(%) of all respective respiratory hospitalizations attributable to RSV infections in adults in Germany, 2015-2019

Age	2015		2016		2017		2018		2019	
groups	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%
Influenza/p	neumonia									
18-44	2.7	2.9	4.2	3.6	4.8	4.4	3.8	3.1	5.0	4.6
	[0, 6.0]		[0, 9.1]		[0, 10.4]		[0, 8.4]		[0, 11.0]	
45-59	3.3	1.3	4.8	1.8	5.2	1.9	4.1	1.4	5.5	2.0
	[0, 8.1]		[0, 11.8]		[0, 13.0]		[0, 10.3]		[0, 13.6]	
60-74	20.4	1.9	20.8	1.8	27.7	2.4	18.1	1.6	23.9	2.2
	[0, 42.6]		[0, 43.6]		[0, 57.9]		[0, 37.9]		[0, 50.0]	
≥75	231.3	4.3	253.7	4.5	292.4	5.1	205.8	3.6	273.9	5.0
l	[137.4, 330.0]		[150.7, 362.0]		[173.7, 417.2]		[122.3, 293.7]		[162.7, 390.8]	
≥60*	73.7	3.4	81.0	3.5	97.9	4.1	67	2.8	88.4	3.9
Bronchitis/I	bronchiolitis									
18-44	0.4	0.9	0.5	1.0	0.6	1.4	0.4	0.9	0.6	1.5
	[0, 2.7]		[0, 3.3]		[0, 4.5]		[0, 3.2]		[0, 4.3]	
45-59	6.6	8.6	7.7	9.2	10.0	11.0	6.9	7.8	9.7	11.1
	[3.4, 10.1]		[4.0, 11.9]		[5.2, 15.4]		[3.6, 10.7]		[5.0, 14.9]	
60-74	25.5	9.0	24.1	8.8	34.4	11.8	21.2	7.3	28.5	10.9
	[14.9, 35.8]		[14.1, 33.9]		[20.1, 48.4]		[12.4, 29.8]		[16.7, 40.1]	
≥75	283.6	19.6	281.9	20.1	359.8	22.4	234.4	16.6	314.2	24.5
	[222.9, 343.8]		[221.6, 341.8]		[282.8, 436.3]		[184.2, 284.2]		[247.0, 381.0]	
≥60*	91.3	15.5	91.5	15.9	121.8	18.7	77.2	13.1	102.9	19.3
Chronic low	ver respiratory tract dise	eases								
18-44	NA		NA		NA		NA		NA	
45-59	18.9	2.4	17.4	2.0	28.1	3.1	17.5	2.0	25.4	2.9
	[1.7, 35.5]		[1.5, 32.7]		[2.5, 52.8]		[1.6, 32.9]		[2.3, 47.8]	
60-74	74.4	2.4	70.4	2.1	100.5	3.0	61.8	1.9	83.3	2.6
	[17.2, 133.8]		[16.3, 126.6]		[23.2, 180.7]		[14.3, 111.2]		[19.2, 149.8]	
≥75	279.5	3.3	239.0	2.6	342.7	3.9	211.4	2.6	293.0	3.6
	[125.7, 432.5]		[107.5, 369.8]		[154.1, 530.3]		[95.1, 327.1]		[131.7, 453.3]	
≥60*	128.9	2.8	116.7	2.3	168.2	3.4	102.9	2.2	140.1	3.1
Upper resp	iratory tract diseases	·						<u> </u>		
18-44	10.9	1.7	10.4	1.5	17.4	2.4	11.1	1.6	15.8	2.3
	[0, 27.3]		[0, 26.1]		[0, 43.7]		[0, 27.8]		[0, 39.7]	

Age	2015		2016		2017		2018	8 2019		
groups	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%
45-59	8.2	1.9	8.1	1.7	12.4	2.5	8.0	1.7	11.4	2.4
	[0, 21.7]		[0, 21.3]		[0, 32.9]		[0, 21.1]		[0, 30.1]	
60-74	18.6	3.6	17.6	3.1	25.1	4.4	15.4	2.8	20.8	3.9
	[0.4, 35.5]		[0.4, 33.6]		[0.6, 48.0]		[0.4, 29.5]		[0.5, 39.8]	
≥75	55.9	7.2	51.2	6.4	70.0	8.4	44.5	5.5	60.6	8.1
	[25.7, 86.4]		[23.5, 79.1]		[32.2, 108.2]		[20.4, 68.7]		[27.8, 93.5]	
≥60*	28.7	4.8	26.9	4.1	37.9	5.8	23.5	3.7	31.7	5.2

CI: confidence interval; IR: incidence rate extrapolated to the national level; NA: not applicable due to data not suitable for modeling

* Based on pooling results for models fitted to adults for included age groups, thus confidence intervals are not provided.

Table 2 Estimated incidence rate per 100,000 person-years of RSV-attributable cardiovascular hospitalizations andpercentage (%) of all respective cardiovascular hospitalizations attributable to RSV infections in adults in Germany, 2015-2019

Age groups	2015		2016		2017		2018		2019	
	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%
Chronic heart fa	ilure exacerbation									
18-44	NA		NA		NA		NA		NA	
45-59	NA		NA		NA		NA		NA	
60-74	65.9 [14.3, 117.0]	2.3	58.2 [12.6, 103.4]	1.9	87.1 [18.9, 154.6]	2.8	52.1 [11.3, 92.4]	1.8	71.4 [15.5, 126.7]	2.4
≥75	302.5 [76.6, 542.1]	1.9	300.7 [76.2, 538.8]	1.8	383.8 [97.2, 687.8]	2.3	250.0 [63.3, 448.1]	1.5	335.1 [84.9, 600.6]	2.1
≥60*	127.9	2.0	123.0	1.8	168.7	2.5	105.3	1.6	141.7	2.2
Ischemic heart of	diseases									
18-44	NA		NA		NA		NA		NA	
45-59	15.4 [0, 34.0]	1.6	15.2 [0, 33.5]	1.5	23.3 [0, 51.5]	2.2	15.0 [0, 33.1]	1.5	21.4 [0, 47.2]	2.1
60-74	92.1 [0.6, 175.4]	1.8	87.2 [0.6, 166.0]	1.6	124.4 [0.8, 236.8]	2.5	76.5 [0.5, 145.7]	1.6	103.1 [0.7, 196.3]	2.1
≥75	357.9 [47.9, 672.1]	1.9	327.7 [43.9, 615.5]	1.6	448.2 [60.0, 841.8]	2.3	284.5 [38.1, 534.4]	1.5	387.5 [51.9, 727.9]	2.1
≥60*	162.5	2.0	152.6	1.8	214.5	2.5	133.3	1.6	179.8	2.2
Arrhythmia										
18-44	NA		NA		NA		NA		NA	1
45-59	16.3 [1.8, 31.8]	2.5	15.0 [1.7, 29.2]	2.0	24.2 [2.7, 47.2]	3.1	15.1 [1.7, 29.5]	2.0	22.0 [2.5, 42.8]	2.9
60-74	108.7 [26.5, 175.8]	2.6	96.1 [23.5, 155.4]	2.2	143.7 [35.1, 232.4]	3.3	85.9 [21.0, 138.9]	2.1	117.8 [28.7, 190.5]	2.8
≥75	460.9 [118.3, 786.7]	2.1	394.2 [101.1, 672.8]	1.6	565.2 [145.0, 964.6]	2.4	348.6 [89.5, 595.0]	1.5	483.1 [124.0, 824.5]	2.0
≥60*	201.5	2.3	176.6	1.8	260.4	2.7	157.2	1.7	215.8	2.3
Cerebrovascular	diseases									
18-44	NA		NA		NA		NA		NA	Τ
45-59	NA		NA		NA		NA		NA	
60-74	NA		NA		NA		NA		NA	
≥75	97.6 [9.9, 189.7]	1.7	83.5 [8.5, 162.2]	1.4	119.7 [12.1, 232.6]	2.0	73.9 [7.5, 143.5]	1.3	102.3 [10.4, 198.8]	1.9

CI: confidence interval; IR: incidence rate extrapolated to the national level; NA: not applicable due to data not suitable for modeling

* Based on pooling results for models fitted to adults for included age groups, thus confidence intervals are not provided.